| Abbvie Inc (ABBV) | |||
|---|---|---|---|
| 158.02 2.72 (1.75%) | 03-24 16:03 | ||
| Open: | 155.28 | Pre. Close: | 155.3 |
| High: | 158.48 | Low: | 154.59 |
| Volume: | 4,583,007 | Market Cap: | 278,769(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 185.10 One year: 216.20 |
| Support: | Support1: 151.12 Support2: 146.57 |
| Resistance: | Resistance1: 158.48 Resistance2: 185.10 |
| Pivot: | 153.61 |
| Moving Averages: | MA(5): 155.98 MA(20): 153.90 MA(100): 154.63 MA(250): 150.43  |
| MACD: | MACD(12,26): 1.16 Signal(12,26,9): 0.75 |
| %K %D: | %K(14,3): 82.40 %D(3): 84.13 |
| RSI: | RSI(14): 60.29 |
| 52-Week: | High: 175.91 Low: 134.09 Change(%): -3.5 |
| Average Vol(K): | 3-Month: 6376 10-Days: 9195 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 158.675 - 159.264 | 159.264 - 159.737 |
| Low: | 153.002 - 153.743 | 153.743 - 154.338 |
| Close: | 156.898 - 158.052 | 158.052 - 158.979 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed below upper band by 10.8%. Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers—General | |
| Shares Out. (M) | 1770.00 |
| Shares Float (M) | 1770.00 |
| % Held by Insiders | 0.12 |
| % Held by Institutions | 71.55 |
| Shares Short (K) | 12700 |
| Shares Short Prior Month (K) | 10300 |
| Stock Financials | |
|---|---|
| EPS | 6.630 |
| Book Value (p.s.) | 9.750 |
| Profit Margin | 20.39 |
| Operating Margin | 38.97 |
| Return on Assets (ttm) | 9.9 |
| Return on Equity (ttm) | 72.4 |
| Qtrly Rev. Growth | 1.6 |
| Gross Profit (p.s.) | 23.463 |
| Sales Per Share | 32.797 |
| EBITDA (p.s.) | 17.565 |
| Qtrly Earnings Growth | -38.80 |
| Operating Cash Flow (M) | 24940.00 |
| Levered Free Cash Flow (M) | 22760.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 23.83 |
| PEG Ratio | -5.61 |
| Price to Book value | 16.21 |
| Price to Sales | 4.82 |
| Price to Cash Flow | 11.21 |
| Stock Dividends | |
|---|---|
| Dividend | 1.480 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
